Abstract
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
Keywords: ACE-2; COVID-19; DARE-19; Dapagliflozin; Renin angiotensin aldosterone system; SGLT-2.
【저자키워드】 COVID-19, Dapagliflozin, ACE-2, DARE-19, Renin angiotensin aldosterone system, SGLT-2., 【초록키워드】 Treatment, Efficacy, SARS-CoV2, Dapagliflozin, sodium, severity, Infection, Diabetes Mellitus, Type 2 diabetes mellitus, drug, diabetes, outcome, aldosterone, ACE-2, Clinical findings, Patient, Complication, RAAS, inhibitor, disease, Glucose, angiotensin, Cardiorenal Disease, CVD, Renin, statistical significance, cascade, COVID-19 pathology, Effect, antidiabetic, cell entry receptor, Course, carried, include, contribute, reducing, demonstrated, Numerous, exacerbate, infected with COVID-19, patients with COVID-19, type 2 diabete, 【제목키워드】 Respiratory failure, Dapagliflozin, Patient, inhibitor, Perspective, Effect, Evaluating, patients with COVID-19,